Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 504-507

  Alimena, Giuliana ^a   Breccia, Massimo ^a   Musto, Pellegrino ^b   Cilloni, Daniela ^d   D'Auria, Fiorella ^b   Latagliata, Roberto ^a   Sanpaolo, Grazia ^c   Gottardi, Enrico ^d   Saglio, Giuseppe ^d   Mandelli, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Bortezomib; Erythroid response; Myelodysplastic sindrome; WT1

Indexed keywords

BORTEZOMIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; ERYTHROID CELL; FEMALE; HUMAN; INCIDENCE; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BORONIC ACIDS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; ERYTHROID CELLS; FEMALE; FEVER; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; THROMBOCYTOPENIA; TREATMENT OUTCOME; WT1 PROTEINS;

EID: 79952364493     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.08.021     Document Type: Article

References (14)

1. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
2. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Epling-Burnette P.K., List A.F. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol 2009, 16:70-76.
4. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol 2008, 142:695-708.
5. Galimberti S., Canestraro M., Pacini S., et al. PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 2008, 32:103-112.
6. Braun T., Carvalho G., Fabre C., Grosjean J., Fenaux P., Kroemer G. Targeting NF-kB in hematologic malignancies. Cell Death Differ 2006, 13:748-758.
7. Braun T., Carvalho G., Coquelle A., et al. NF-kB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107:1156-1165.
8. Jackson G., Einsele H., Moreau P., San Miguel J. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005, 31:591-602.
9. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
10. Cilloni D., Gottardi E., Messa F., et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System score in patients with myelodysplastic syndromes. J Clin Oncol 2003, 21:1988-1995.
11. Shetty V., Verspoor F., Nguyen H., et al. Effect of proteasome inhibition by bortezomib on tumor necrosis factor alpha (TNFa) and apoptosis in patients with myelodysplastic syndromes (MDS). Blood 2003, 112. (abstr 1534).
12. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
13. Terpos E., Verrou E., Banti A., Kaloutsi V., Lazaridou A., Zervas K. Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. Leuk Res 2007, 31:559-562.
14. Lonial S., Walker E.K., Richardson P.G., et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106:3777-3784.